Endometrial carcinoma is one of the most common cancers in women. A limited number of endometrial carcinoma cell lines are available for studies of signal transduction pathways and experimental therapeutics in vitro. However, these cell lines have not been comprehensively characterized. In this study, we used genome-wide microarray-based comparative genomic hybridization (aCGH) technology to characterize five of the more commonly used endometrial cancer cell lines. We detected DNA copy-number gains in chromosomal regions 2q, 3p, 3q, 5q, 7p, 17q, and19q in all five cell lines. Other common sites of copy-number gains, which were detected in four of five cell lines, included segments of chromosomes 1, 6, 8, 9, 11, 12, and 16. In all five cell lines, we found DNA copy-number losses in regions 3p, 10p, 10q, 11q, 11p, 14q, 15q, 18p, and 21q. Other common sites of genetic aberrations included segments of chromosomes 1, 2, 4, 5, 6, 16, 20, and 22. The genes involved in the copy-number alterations included the oncogenes PIK3CA (3q26.3), K-ras (12p12.1), R-ras (19q13.3-qter), Raf-1 (3p25), EGFR (7p12), Akt1 (14q32.32), and Akt2 (19q13.1-q13.2). A pathway analysis showed that genes in the PI3K and Wnt pathways are commonly affected.
Introduction
Endometrial carcinoma (EC) is the leading cancer of the female genital tract in the United States and the fourth most common cancer among women after breast, lung, and colorectal cancer. In the United States, 42,160 new cases and 7,780 deaths from EC are expected in 2009 (1). EC is commonly classified into two categories: type I estrogen-dependent EC and type II nonestrogen-dependent EC. The majority of ECs are type I (approximately 70% to 80%), which generally have low-grade endometrioid histologies, often arising in a background of endometrial hyperplasia. In contrast, the less common type II ECs often arise in a relatively atrophic endometrium and are characterized by nonendometrioid histologies and a more aggressive clinical course (2). On the basis of their distinct clinico-pathological characteristics, the molecular alterations in these two types of EC appear to be different. Chromosomal abnormalities, including DNA copy-number gains and/or losses are DNA sequences were classified as recurrent aberrations if the number of aberration labels given to them exceeded a threshold of statistical significance. A permutation test was applied to estimate the value of this threshold. The aberration labels of the targets were permutated, and sums of the gain and loss labels were computed for each target. Gains and losses were considered separately in this procedure; therefore, both genomic states had different statistical significance thresholds. The 99th percentile values for both sums were chosen hallmarks of cancers (3) . In a comparative genomic hybridization (CGH) study of 98 cases of EC, Levan et al., (4) reported frequent amplifications in the chromosomal regions 1q25-42, 19pter-p13.1, 19q13.1-q13.3, 8q21-22, 10q21-q23, and 10p , and frequent losses in the regions 4q22-qter, 16q21qter, and 18q21-1ter. Another CGH analysis of 43 human primary ECs revealed gains at 1q25-q41, 8q11.1-q21.1, and 8q21.3-qter, whereas the most frequently detected loss was at 16q11. 2-q22 (5) .
At the gene level, the most frequent genetic alteration of type I ECs is PTEN inactivation (mutation), followed by microsatellite instability (MSI), and mutations of K-ras and ß-catenin; activation of the PI3K pathway is common as well. Mutation of PIK3CA is seen in 36% of type I ECs and is most common in tumors with PTEN mutations (6). Oda et al., (7) reported that PIK3CA mutations coexisted with K-ras and PTEN mutations in EC, and mutant levels of p-AKT (Ser473) induced by mutant Ras or knockdown of PTEN were dramatically increased by addition of mutant PIK3CA. Catasus et al., showed that PIK3CA mutations occurred in 29% (32/109) of the endometrioid adenocarcinomas they studied, and all had myometrial invasion (8). Recently, the authors also found that EC patients with a deregulated PI3K/ AKT pathway (exon 20 PIK3CA and/or PTEN mutation) and p53 alterations had worse prognosis than patients with only p53 alterations (9). Conversely, p53 mutation is the most frequent genetic alteration in the more aggressive type II EC. Other frequent events in type II ECs include inactivation of p16, loss of E-cadherin, and amplification of human epidermal growth factor receptor 2 (HER2)/neu (10) (11) (12) (13) (14) . Identification of gene amplifications has critical implications for the development of targeted therapeutics. The recent discovery of frequent PIK3CA gene mutations in ECs has led to translational investigations of whether blocking the PI3K pathway is a viable approach for the treatment of ECs.
The current paradigm of cancer translational research relies heavily on the use of cancer cell lines derived from patients. A loss-of-function approach, using small interfering RNA (siRNA) or small-molecule inhibitors is commonly used to block the suspected oncogenic targets that are often amplified, mutated, and/or overexpressed in cancer. A gain-offunction approach by transfection of an expression vector is commonly used to investigate the potential tumor-suppressing function of genes that are commonly deleted in cancers. Therefore, characterization of in vitro cell model systems is important for the selection of the appropriate cell lines for future investigations. In this report, we describe the results of a comprehensive analysis of five commonly used EC cell lines by array CGH (aCGH) to identify the most commonly occurring gene copy-number aberrations. We also discuss our findings regarding these gene aberrations in relation to the PI3K/Akt, Wnt/b-catenin, and other important cancer-related as thresholds of significance. Contiguous DNA sequences whose true aberration-label counts exceeded the significance threshold formed segments of recurrent aberrations. These segments varied in length from one gene to a whole chromosome. A mean of the aberration counts for sequences in a recurrent aberration segment (probe average recurrence) was computed as a rough measure of the recurrence rate for the segment. All of the aCGH data will be deposited in the GEO (Gene Expression Omnibus) database.
Results

Detection of Common DNA Copy-Number Aberrations in Five EC Cell Lines
Genomic DNA was isolated from the five EC cell lines and used for whole genome aCGH. The global patterns of gene copynumber aberrations of the five EC cell lines are shown in Figure 1 . Among the five cell lines, the HEC1A and HEC1B cell lines exhibited more observable alterations than the other three. Because all five EC cell lines were derived from type I ECs, which are known to be mostly diploid, the global aCGH patterns of these cell lines appear to be consistent with what is known about type I primary ECs. Nevertheless, gene copynumber aberrations were clearly observed from the aCGH analysis.
We first sought to identify the most frequently altered regions in either all five or in four of the five cell lines. The result of the frequency analysis is illustrated in Figure 2 and summarized in Table I . In all five EC cell lines, chromosomal regions 2q37.1, 3p21, 3q29, 5q23, 5q31, 7p15, 17q12-q25, and 19q13 were significantly amplified, whereas regions 3p12-14, 10p11, 10q11, 11p11, 11q11, 11q23, 14q31, 15q25, 18p11, and 21q11 showed significant deletions. These regions included 67 genes with amplifications and 45 genes with deletions (Table I) . Among the amplified genes were R-Ras and PIK3CA (in four of five lines), representing two pathways known to be activated in EC. The Wnt pathway gene Wnt8A was also amplified in all cell lines, as were the cancer stem cell -related ALDH gene family members ALDH7A1 and ALDH16A1. The list of commonly deleted genes did not reveal the bestknown tumor suppressor genes, such as TP53, p16Ink4a, Rb, and PTEN. Since these cell lines are derived from type I endometrioid tumors, these results were not unexpected. In type I EC, loss of PTEN is most frequently due to mutation. The lack of deletion of these tumor suppressors may indicate that these cell lines, despite being passaged in vitro many times, tend to stay true to their parent tumors.
Alterations of Genes in Key Pathways Associated with EC Tumorigenesis
Examination of the most commonly altered genes sheds light on the potential key drivers of tumorigenesis; however, cancer is also known for its heterogeneity and complex oncogene interactions in a pathway context. In other words, different genes in a common pathway may be altered in different cancers but the effects can be similar. Therefore, we next performed a pathway-centric analysis and examined the genes involved in the best-characterized oncogenic pathways among the five EC cell lines.
Activation of the PI3K/Akt pathway plays an important role in EC, and PIK3CA is mutated in 24% to 39% of type I ECs (6, 7, 17, 18) . Our analysis showed that many genes in this pathway, in addition to PIK3CA, were amplified in EC cell lines (Table II) . Interestingly, Akt1 and Akt2 were co-amplified in the ECC-1 and Ishikawa cell lines, whereas Akt3 was deleted in these two cell lines. Akt1 and AKt3 were also deleted in the metastatic AN3CA line, whereas there was no significant aberration in Akt2. Overall, the ECC-1 and Ishikawa lines had amplification of many more PI3K/Aktpathway genes than the other three cell lines.
Another EC-related gene, b-catenin, acts as a downstream transcriptional activator in the Wnt signal-transduction pathway, which has been reported to be activated in EC (19) . Gain-of-function mutations in the b-catenin gene are found in 25% to 38% of type I ECs (20). Of the five EC cell lines tested, we found that many Wnt-pathway genes were amplified in the ECC-1 and Ishikawa cell lines (Table III) .
Receptor tyrosine kinases (RTKs) are often amplified in human cancers and they represent a class of proteins that are considered excellent therapeutic targets. Examination of the five EC cell lines showed that EphB3 and EphB4 were the most commonly amplified RTK genes, and a number of other Eph members were also amplified in these cell lines (Table IV) . EGFR was significantly amplified in the AN3CA, HEC1A, and HEC1B cell lines. However, IGF1R, which has been shown to be amplified in some sarcomas, was not amplified in these cell lines. FGFR genes were amplified in four of five cell lines, while the ErbB2 gene was amplified in three of five. MET was only amplified in the HEC1B and metastatic AN3CA cell lines. The ECC-1 and Ishikawa cell lines harbored most of the RTK gene amplifications, whereas the HEC1B cell line had the least.
Among the common cancer-related oncogenes, R-Ras was amplified in all cell lines and Raf-1 was amplified in four of five cell lines (Table V) , consistent with reports of mutations of these oncogenes in EC patients (11, 21) . We also found that K-Ras, MDM1, and MDM2 were amplified in three of five cell lines.
There were no significant alterations in cell cycle -related genes in the EC cell lines, except for Cdk3, which was amplified in four of five cell lines (Table VI) . Although no Tumor-suppressor gene deletion was not a common event in the five EC cell lines, with the exception of p16, which was deleted in two EC cell lines (Table VIII) . Some of the genes, such as VHL, were actually amplified in EC, although it is not clear whether these genes had inactivation mutations or not.
Discussion
In this study, we used genome-wide aCGH technology to characterize the gene copy-number aberrations in five of the most commonly used EC cell lines. Although limited in scale (the results need to be further compared in a bigger study with a large number of primary EC samples) we have obtained valuable information that provides some insight into the genetic signatures of EC cells. First, the global gene copy-number aberration patterns of the five EC cell lines were less complex than patterns reported for many other cancer cell lines. This suggests that the EC cell lines have not undergone major changes during multiple in vitro passages in the laboratory and, thus, still exhibit the molecular characteristics of the primary type I EC cells, which are known to be more diploid. Therefore, the five cell lines studied represent good model systems for studying EC signaling pathways and, perhaps, therapeutics in vitro and in preclinical animal model experiments. To support this notion, the consistent gains or losses we identified (gains in 2q, 3q, 3p, 5q, 17q, 7p, and 19q and losses in 3p,10p, 10q, 11q, 11p, 14q, 15q, 18p, and 21q) are consistent with those reported for EC patients (4, 5).
Many of the amplifications identified in our study are relatively small in scale. We believe this is also the result of tumor heterogeneity and the co-existence of multiple clones in each cell line. Although this can be further tested by serial dilution and clonal expansion experiments, the results from the HEC1A and HEC1B cell lines, which were derived from the same patient, support this hypothesis. Most of the altered genes are shared between the HEC1A and HEC1B lines, such as amplification on chromosome 3p and deletions on chromosome 1p and 4q. However, there are a few HEC1Bspecific gene deletions present, such as InsR, IGF1R, ALK, ESR1, ESRRA, and AR. Thus, these two cell lines may be useful as "isogenic" control lines for the study of EC responses to insulin and IGF.
Our detailed analysis of key oncogenic pathway genes provides additional insights that are relevant to many areas of EC research. O'Toole et al., (22) examined eight EC specimens by aCGH and also found amplification of some of the same oncogenes, including AR, PIK3CA, MET, HRAS, NRAS, 17S1670, FGFR, CTSB, RPS6KB1, LAMC2, MYC, PDGFRA, FGF4/FGF3, PAKI, and FGR. Below, we discuss a few of the major pathways of particular interest in EC in more detail. significant alterations were observed in the apoptosis-related genes in these EC cell lines (Table VII) , it was interesting that many of these genes were deleted in the HEC1B cell line but amplified in the ECC-1 and Ishikawa cell lines. 
Cytogenetic location Genes
Regions of gain
Technology in Cancer Research & Treatment, Volume 9, Number 2, April 2010 deletion in HEC1B in all of the five EC cell lines we tested, the PIK3CA gene, which encodes the p110α catalytic subunit of PI3K, is amplified in four of the five EC cell lines. We have not performed a sequencing analysis and, therefore, do not yet know whether PIK3CA is mutated. However, it would not be surprising if mutations also occur in this gene, as mutation of the PIK3CA gene has recently been found in 24% to 39% of type I ECs, and these mutations are correlated with poor prognosis (6-9, 17, 18) . Amplification of PIK3CA has also been identified in ovarian cancer (29), non-small cell lung cancer (30), squamous cell carcinoma of the oral tongue (31), and cervical cancer (32), as well as in EC (22). Therefore, PIK3CA amplification plays an important role in the tumorigenesis of a wide spectrum of solid tumors.
Akt, one of the downstream effectors of PI3K, is an evolutionarily conserved serine/threonine kinase that has three isoforms: Akt1, Akt2, and Akt3. Once activated, Akt regulates multiple cellular functions such as cell proliferation, survival, apoptosis, glucose metabolism, ribosomal function, transcription, and cell migration (33, 34). The expression of Akt1 and Akt2 is ubiquitous, whereas Akt3 is expressed predominantly in the brain, heart, and kidney (35). The emerging picture from recent studies is that the three Akt isoforms play different roles in different cancers. For example, in breast cancer, Akt3 is upregulated in ER-negative breast carcinomas (36), and overexpression of Akt2 could stimulate tumor cell invasion both in vitro and in vivo (37). A recent report by Irie et al., (38) showed that silencing Akt1 expression with shRNA actually increased cell migration, whereas silencing Akt2 had no effect on nontransformed MCF10A breast epithelial cells. Gagnon et al., (39) showed that Akt1 mRNA and protein were present in both PTEN/PI3K/Akt Pathway: PTEN, which is located on chromosome 10q23.3, has been reported to be altered (mostly by mutation and less frequently by loss of heterozygosity) in up to 83% of type I ECs (23) (24) (25) . Inactivation of PTEN through deletion and mutation results in activation of the PI3K/Akt pathway, which is important for cell proliferation, apoptosis, and migration in EC (26-28). Although we only detect PTEN (40), renal cancer (41), ovarian cancer (42), and EC (19). Wang et al., (43) reported that progesterone inhibits Wnt signaling in the human endometrium through induction of DKK1 and FOXO1. The inhibitory effect of progesterone on Wnt signaling may, in part, play a role in the maintenance of endometrial homeostasis. Wagner et al., (44) found that the estrogen receptor is involved in the regulation of Wnt7a in Ishikawa cells and the modulation of Wnt gene expression by estrogen might be a novel mechanism for EC tumorigenesis. The aCGH results of our study show that there were significant alterations in the genes in the Wnt/b-catenin pathway. Wnt8A, Wnt10B, and CSNK1A1 were amplified in all five cell lines, while Wnt7A, Wnt9B, and GSK3B were amplified in four of five cell lines. Most genes in this pathway were amplified in the ECC-1 and Ishikawa cells, which predominantly express estrogen receptor (45, 46) . Thus, these two cell lines may represent ideal model systems for studying the relationship between the Wnt pathway and the hormone response and their roles in EC tumorigenesis.
The Ras-Raf Pathway. Our study showed that R-Ras was amplified in all cell lines and that K-Ras and C-Raf were amplified in four of five cell lines. Ras mutation is a well-recognized event in EC. The Raf family of proto-oncogenes encodes cytoplasmic serine/threonine protein kinases, which play a pivotal role in cell growth and oncogenesis. B-Raf has been found to be activated by mutations in a multitude of human cancers (47-49). However, most of the analyses have shown a low prevalence of B-Raf mutations in EC (50-52). More HEC1A and KLE EC cells, whereas Akt2 and Akt3 mRNAs and proteins were strongly expressed in KLE cells. Knockout of Akt isoforms increased the sensitivity of KLE cells toward cisplatin and caused a significant induction of cell death. In this study, we found that Akt2 was significantly amplified in four of five EC cell lines, and Akt1 was amplified in two of interestingly, B-Raf mutation was more frequently found in hMLH1-negative than hMLH1-positive EC cases (53). Alterations in C-Raf expression have been suggested to play a role in melanoma and lung cancer (54, 55) . In this study, we found that C-Raf was amplified in four of five EC cell lines, suggesting that C-Raf is a key isoform for EC oncogenesis. To date, the role of A-Raf in tumorigenesis has not been published. However, recently, Hagemann et al., (56) found A-Raf expression did not have any influence on the proliferation or migration of glioblastoma cells, and A-Raf expression was negatively associated with prognosis in patients with glioblastomas. Therefore, A-Raf may be a negative regulator of cell metabolism (57, 58 Eph Receptor Pathway: Eph receptors constitute the largest family of RTKs and are involved in a wide range of processes directly related to tumorigenesis and metastasis (60). Our aCGH data showed that EphB3 (3q21-qter) and EphB4 (7q22) were amplified in four of five EC cell lines and EphA2, which has been reported to be overexpressed in EC (61), was amplified in two of the cell lines. Takai et al., (62) analyzed 20 cases of EC and 20 normal endometrial cases, and found that EphB4 expression was significantly associated with histological grade and certain clinical stages, while Ephrin-B2 expression was significantly associated with the presence of deeper invasion. In addition, Berclaz et al., (63) showed that the EphB4 protein was not detected in normal endometrial tissue, but increased drastically in the majority of hyperplasias and carcinomas. These studies together provide strong evidence that EphB4 activation is likely an early oncogenic event in EC development and may represent an important diagnostic/ prognostic marker and a target for therapeutic intervention. At the present time, little is known about other Eph receptors' roles in EC, although, EphB3 was reported to be amplified in lung and colon cancers and in rhabdomyosarcoma (64-66).
In summary, our genomic characterization of commonly used endometrial cancer cell lines, although limited in scale and needing further validation studies using primary tumor tissues, provides potentially important insights into the genetic events that underly the tumorigenesis of this common type of cancer. Further investigations using primary EC cells, as well as functional studies with these in vitro EC cell models coupled with preclinical mouse model experiments, should allow the identification of clinical markers for diagnosis/ prognosis and potential molecular targets for therapeutic intervention.
